贝那普利对糖耐量减低患者的干预作用

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (9): 1061-1064.

贝那普利对糖耐量减低患者的干预作用

夏礼斌, 黄晓晖¹, 孙瑞元²

皖南医学院弋矶山医院内分泌科,²安徽省药物临床评价中心芜湖241001, 安徽;
¹安徽医科大学药学系, 合肥230032, 安徽

收稿日期:2004-08-14 修回日期:2004-09-10 出版日期:2004-09-26 发布日期:2020-11-23
通讯作者: 夏礼斌, 男, 硕士, 讲师, 主治医师, 研究方向:内分泌与免疫药理学。Tel:0553-5739315 E-mail:xialibin220 @yahoo. com. cn
作者简介:孙瑞元, 男, 教授, 主任, 研究方向:定量药理学与生物统计学。

Intervention of bennazepril in the patients with impaired glucose tolerance

XIA Li-Bin, HUANG Xiao-Hui¹, SUN Rui-Yuan²

Department of Endocrinology, Yijishan Hospital of Wannan Medical College,²Anhui Provincial Center for Drug Clinical Evaluation, Wuhu 241001, Anhui, China;
¹Department of Pharmacology, Anhui Medical University, Hefei 230032, Anhui, China

Received:2004-08-14 Revised:2004-09-10 Online:2004-09-26 Published:2020-11-23

摘要/Abstract

摘要： 目的: 观察贝那普利对糖耐量减低(IGT) 患者的干预作用。方法: 75 g 葡萄糖耐量试验(OGTT) 确诊IGT 70 例, 其中男31 例, 女39 例, 随机分成贝那普利组、对照组各35 例。对照组进行饮食、运动控制, 贝那普利组除饮食、运动控制外, 加贝那普利10 mg qd, 观察12 周。结果: 治疗后两组空腹血糖(FBG) 及舒张压均下降, 但两组间差异无显著的统计学意义(P >0. 05); 对照组治疗后收缩压无下降, 而贝那普利组有所下降(P<0. 01); 两组治疗后的餐后2 h 血糖(P2HBG) 及糖化血红蛋白(HbA_1c) 均下降, 贝那普利组优于对照组(P<0. 05) 。结论: 贝那普利可降低糖耐量减低患者P2HBG 、HbA_1c及收缩压水平, 提示贝那普利可改善糖耐量减低患者代谢紊乱。

关键词: 糖耐量减低, 贝那普利, 空腹血糖, 餐后2 h 血糖, 糖化血红蛋白

Abstract: AIM: To explore the intervention of bennazepril in patients with impaired glucose tolerance (IGT).METHODS: Seventy patients with first diagnosed IGT were enrolled in this study. The control group involved 35 patients dealt with diet and exercise, and the trial group involved 35 patients dealt with diet, exercise and bennazepril. The changes of fasting blood glucose (FBG), 2-hour postprandial blood glucose (P2HBG ), systolic blood pressure (SBP), diastolic blood pressure (DBP) and glycosylated hemoglobin (HbA_1c) values were assayed.RESULTS: After the treatment of 12 weeks, the decreased values of fasting blood glucose and diastolic blood pressure were not difference (P >0. 05), but in the trial group, decreased values of 2-hour postprandial blood glucose and glycosylated hemoglobin A_1c decreased (P<0. 05), and systolic blood pressure also decreased (P<0. 01).CONCLUSIONS: Bennazepril can decrease the 2-hour postprandial blood glucose, glycosylated hemoglobin A_1c and systolic blood pressure. It suggests that Bennazepril can improve the metabolic disorder in patients with IGT.

Key words: impaired glucose tolerance, bennazepril, fasting blood glucose, 2 hour postprandial blood glucose, glycosylated hemoglobin A_1c

中图分类号:

R972

夏礼斌, 黄晓晖, 孙瑞元. 贝那普利对糖耐量减低患者的干预作用[J]. 中国临床药理学与治疗学, 2004, 9(9): 1061-1064.

XIA Li-Bin, HUANG Xiao-Hui, SUN Rui-Yuan. Intervention of bennazepril in the patients with impaired glucose tolerance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1061-1064.

参考文献

1 李春霖, 陆菊明, 潘长玉, 朱艳, 王淑玉, 田慧等.糖耐量减低者两年后的转归[J]. 中华内分泌代谢杂志, 1997;13 (2): 86-9
2 叶任高.内科学[M]. 第5 版.北京:人民卫生出版社, 2002:810
3 Kwame O, Scott R, Trudy G, RN, Dara Schuster. Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic african americans[J]. Diabetes Care, 2004; 27(6): 1439-46
4 David W, Dunstan, Paul Z, Zimmet, Timothy A.Welborn, et al. The Rising Prevalence of Diabetes and Impaired Glucose Tolerance[J]. Diabetes Care, 2002;25(5): 829-34
5 全国糖尿病协作组.1994 年中国糖尿病患病率及其危险因素[J]. 中华内科杂志, 1997; 36(6): 384-9
6 The diabetes prevention program (DPP) research group. The diabetes prevention program (DPP) [J]. Diabetes Care, 2002; 25 (12): 2165-71
7 Jakko T, Jaana L, Johan G, Eriksson, Timo T, Valle, et al. Finnish diabetes prevention study group. Prevention of type 2 diabetes mellitus by changes in lifesty le among subjects with impaired glucose tolerance[J]. N Engl J Med, 2001;344(18): 1343-50
8 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM trial research group. Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial[J]. Lancet, 2002;359(9323): 2072-7
9 杨文英, 林丽香, 齐今吾, 于志清, 裴海成, 何国芬.阿卡波糖和二甲双胍对IGT 人群糖尿病预防的效果-多中心3年前瞻性观察[J]. 中华内分泌代谢杂志, 2001;17(3): 131-4
10 陈宇, 王志武.血管紧张素转换酶抑制剂在某些疾病中的应用[J]. 国外医学老年医学分册, 2000; 21(1): 13-5
11 The heart outcomes prevention study investigators.Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovasculor events in high-risk patients[J]. New Eng J Med, 2000; 342(3): 149-53
12 Zachary T, Bloomgarden. Treatment of Type 2 Diabetes:The american association of clinical endocrinologists meeting[J]. Diabetes Care, 2002;25(9): 1644-9
13 Zachary T, Bloomgarden.The American association of clinical endocrinologists (aace) consensus conference on the insulin resistance syndrome[J]. Diabetes Care, 2003; 26(4): 1297-303

[1]	范剑峰，方译，郑春华. 沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(7): 810-814.
[2]	孔祥，华强，孟祥健，姚新明，王勇，夏礼斌. 初诊2型糖尿病患者循环miRNA-101的表达变化及临床意义[J]. 中国临床药理学与治疗学, 2017, 22(12): 1406-1409.
[3]	刘长乐, 龚成欣, 熊超鹏, 何鹿玲, 饶燊强, 肖雯, 彭露露, 汤澜, 许永虎, 徐宏. 体重指数影响骨钙素基因HindIII多态性与中国绝经前妇女空腹血糖间的关联[J]. 中国临床药理学与治疗学, 2015, 20(9): 1026-1031.
[4]	杨沿浪, 邹和群, 张道友, 汪裕伟, 李芳霞, 高超清, 徐海红, 陈小妹. 贝那普利、螺内酯联用对阿霉素肾病大鼠肾小管保护作用的研究[J]. 中国临床药理学与治疗学, 2012, 17(4): 381-386.
[5]	邓阿黎, 向楠, 周忠明, 姜惠中, 张亚兵. 复方中药对多囊卵巢综合征模型大鼠糖代谢的影响[J]. 中国临床药理学与治疗学, 2009, 14(5): 504-508.
[6]	黄一玲, 田蕾, 蒋娟娟, 华潞, 刘红, 李一石. 贝那普利对氨氯地平药代动力学的影响[J]. 中国临床药理学与治疗学, 2008, 13(2): 174-178.
[7]	陈碧莲, 刘慧霞, 潘瑞喆. 葡萄糖耐量减低患者二甲双胍干预治疗的临床效果[J]. 中国临床药理学与治疗学, 2007, 12(1): 107-110.
[8]	夏礼斌, 陆美琴, 张斌华, 张安素, 陈月平, 华强, 冒国光. 国产那格列奈片对2型糖尿病疗效的临床评价[J]. 中国临床药理学与治疗学, 2004, 9(8): 932-934.